Revolo Announces Fireside Chat at Canaccord Genuity’s 44th Annual Growth Conference
August 07, 2024 08:45 ET
|
Revolo Biotherapeutics
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that President and Chief Executive Officer, Woody Bryan,...
Revolo Announces New Data Further Validating the Upstream Mechanism of Action and Subcutaneous Administration of ‘1104
July 24, 2024 08:45 ET
|
Revolo Biotherapeutics
Reduction of key proteins in the interleukin 4 (IL-4) and IL-13 signalling pathway via SHP-1 activation is a key component involved in the mechanism of action of ‘1104First-in-class upstream approach...
Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May
May 14, 2024 08:00 ET
|
Revolo Biotherapeutics
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, May 14, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis
January 30, 2024 08:30 ET
|
Revolo Biotherapeutics
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
November 07, 2023 10:05 ET
|
Revolo Biotherapeutics
- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) - NEW ORLEANS and CAMBRIDGE, United Kingdom, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Revolo...
Revolo Biotherapeutics Announces Data from Study of ‘1104 in Atopic Adults
October 25, 2023 08:00 ET
|
Revolo Biotherapeutics
- Treatment with ‘1104 demonstrated a rapid reduction in intradermal allergic inflammation - - Treatment with ‘1104 induced sustained activation of T regulatory and B regulatory cells, providing...
Revolo Biotherapeutics to Present Data from Phase 2a Clinical Trial of ‘1104 in Eosinophilic Esophagitis at ACG 2023
October 17, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Announces the Completion of Phase 1 Multiple Ascending Dose Clinical Trial of ‘1104
September 21, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics to Host Virtual KOL Event on ‘1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
August 08, 2023 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and CAMBRIDGE, United Kingdom, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to...
Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
July 18, 2023 08:00 ET
|
Revolo Biotherapeutics
- Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo - - Unique broad mechanistic effect across a range of key cell types associated with EoE...